Personalized medicine · 2026
The association between DNA repair genes polymorphisms and cisplatin-induced ototoxicity in cancer patients: a systematic review.
Систематический обзорСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Omar Nabil E, Mekkawi Rana, Said Salma, Abd Elrahman Omar, Hawasly Fatima, Hamad Anas, Elewa Hazem
Аннотация
INTRODUCTION: Ototoxicity is a dose-limiting toxicity of cisplatin. Several DNA repair gene polymorphisms have been investigated for their association with cisplatin-induced ototoxicity (CIO), but their predictive value remains controversial. This systematic review evaluated genetic predisposition to CIO via DNA repair gene polymorphisms.
METHOD: PubMed, SCOPUS, Web of Science, trial registries, and gray literature sources were searched, and reference lists of included studies were screened. Study quality was assessed using the Q-Genie tool, and reporting followed PRISMA guidelines. The protocol was registered on PROSPERO (ID: CRD420251112849).
RESULTS: Eight studies with 672 subjects were deemed eligible, investigating nine DNA repair genes (XPA, XPC, ERCC1, ERCC2, XRCC1, EX01, ERCC4, and ERCC5), covering 96 single-nucleotide polymorphisms (SNPs), 54 of which were in DNA repair pathways. AC+CC genotypes of XPC rs2228001 were associated with decreased risk of CIO (OR: 0.20, 95% CI: 0.06-0.70, p = 0.01). Conversely, combining XPC rs2228001 with SNPs in GSTP1, FASL, or MSH3 showed the highest risks (ORs of 32.22, 22.29, and 17.09).
CONCLUSION: Although several DNA repair gene polymorphisms have been explored, findings remain inconsistent and limited by populations and SNPs studied. Larger, well-designed studies with standardized methodologies are needed to confirm these associations and identify genetic markers for predicting high-risk patients for CIO.
METHOD: PubMed, SCOPUS, Web of Science, trial registries, and gray literature sources were searched, and reference lists of included studies were screened. Study quality was assessed using the Q-Genie tool, and reporting followed PRISMA guidelines. The protocol was registered on PROSPERO (ID: CRD420251112849).
RESULTS: Eight studies with 672 subjects were deemed eligible, investigating nine DNA repair genes (XPA, XPC, ERCC1, ERCC2, XRCC1, EX01, ERCC4, and ERCC5), covering 96 single-nucleotide polymorphisms (SNPs), 54 of which were in DNA repair pathways. AC+CC genotypes of XPC rs2228001 were associated with decreased risk of CIO (OR: 0.20, 95% CI: 0.06-0.70, p = 0.01). Conversely, combining XPC rs2228001 with SNPs in GSTP1, FASL, or MSH3 showed the highest risks (ORs of 32.22, 22.29, and 17.09).
CONCLUSION: Although several DNA repair gene polymorphisms have been explored, findings remain inconsistent and limited by populations and SNPs studied. Larger, well-designed studies with standardized methodologies are needed to confirm these associations and identify genetic markers for predicting high-risk patients for CIO.